This study investigates the relationship of circulating microRNA-30e and schizophrenia, and shows the relevance of the aberrant microRNA-30e expression in plasma with the variation disease status.
The plasma samples from 15 individuals with schizophrenia (with a diagnosis of ICD-10) and the equivalent healthy controls will be conducted with the quantification analysis of the microRNA-30e via real-time quantitative polymerase chain reaction(RT-PCR). The 15 patients enrolled should be the first-episode and have not been treated, or were drug free 3 months recently at least. This research measures the expression level of microRNA-30e in schizophrenia respectively before the beginning treatment with atypical psychotics or combined with MECT, after the 4-week treated , the 8-week treated compared with 15 healthy controls.
Study Type
OBSERVATIONAL
Enrollment
30
Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
Dalian Seventh People's Hospital
Dalian, Liaoning, China
RECRUITINGthe Baseline expression profiling of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR)
the plasma samples will be collected from the patients with schizophrenia and the healthy controls at the beginning recruit for the microRNA-30e detection
Time frame: before the treatment
the Changed expression level of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR)
the plasma samples will be collected from the patients with schizophrenia at the 4-week treatment for the microRNA-30e detection
Time frame: Change from Baseline expression level at 4-week treatment
the Changed expression level of microRNA-30e measured by real-time quantitative poly-chain reaction (QPCR)
the plasma samples will be collected from the patients with schizophrenia at the 8-week treatment for the microRNA-30e detection
Time frame: Change from Baseline expression level at 8-week treatment
the scores of Positive and Negative Syndrome Scale(PANSS) for the patients with schizophrenia
The PANSS for estimating the severity of positive and negative symptoms in schizophrenia
Time frame: before, after 4 weeks and 8 weeks treatment
The degree of Personal and Social Performance scale(PSP) for the patients with schizophrenia
The degree of Personal and Social Performance scale(PSP) used to evaluate the disable levels in Multiple dimensions ,especially in social and self-care performance
Time frame: before, after 4 weeks and 8 weeks treatment
The scale of Clinical Global Impression(CGI) in patients with schizophrenia after treatment
Main purpose to provide a global rating of illness severity ,improvement and response to treatment for the patients with schizophrenia
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 4 weeks and 8 weeks treatment